Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | SOX18 | P35713 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Menaphthyl Sulfonate SCHEMBL294032 | 0.98 | CYP1A2 (0.50) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL28420721 | 0.82 | CA2 (0.44) | — | |
| SCHEMBL27450675 | 0.82 | CYP1A2 (0.54) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| Tetrabuthylammonium SCHEMBL6739959 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL30457820 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP2A6 | |
| SCHEMBL28424655 | 0.81 | CA2 (0.43) | — | |
| SCHEMBL28423010 | 0.81 | CYP1A2 (0.43) | CYP1A2NLRP3 | |
| SCHEMBL294031 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| Sulfuric Acid SCHEMBL4093062 | 0.80 | TEAD4 (0.55) | CYP1A2CYP2A6NPY1RNPY5RTEAD4 | |
| SCHEMBL28422970 | 0.79 | ESR1 (0.43) | CYP1A2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559461-A1 | DUAL NLRP1 AND NLRP3 INHIBITORS FOR USE AS A MEDICAMENT | Servicio Andaluz De Salud (ES) | 2025-05-28 | — | — | EP | disclosed |
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| EP-1280800-A1 | N-SULFONYL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF CD 23 | SMITHKLINE BEECHAM PLC (GB) | 2003-02-05 | — | — | EP | disclosed |
| EP-1265855-A1 | NOVEL CD23 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001085721-A1 | N-SULFONYL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF CD 23 | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001062715-A1 | NOVEL CD23 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | CYP1A2 3498/4885CYP2A6 2368/4885HTR2A 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.